Antikor - Crunchbase Company Profile & Funding

Overview

Antikor

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Antikor

CB Rank

814946

Breakthrough cancer therapy: Next-generation Antibody Fragment Drug Conjugates

Founded

obfuscation

Private

Stevenage, Herefordshire, United Kingdom

1-10

www.antikor.co.uk/

Biotechnology

Health Care

Key People

Mahendra Deonarain Deonarain: Chief Executive Officer
Past Role: Imperial College London, Reader in Antibody Technology & Therapeutics
Bryan Edwards: Head of Antibody Discovery
Past Role: Crescendo Biologics, Head of In Vitro Platforms

Details

Operating Status

Active

Company Type

For Profit

Phone Number

+4401438906906

Contact Email

enquiries@antikor.co.uk

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Antibody Fragment Drug Conjugates (FDCs)

Small fully-human antibody fragments linked to cytotoxic drugs designed for targeted delivery to solid tumors, improving penetration and reducing side effects compared to traditional ADCs.

OptiLink Technology Platform

A proprietary platform enabling the creation of antibody fragment drug conjugates with high drug-to-antibody ratios and optimized stability for cancer therapy development.